TRANSCENTA-B (06628) completed the issuance of a total of 14.4 million shares for subscription.
Chuangsheng Group-B (06628) announced that all conditions for the placement have been met and the placement will be completed by 2025.
TRANSCENTA-B (06628) announcement that all conditions for the placing have been met and the completion of the placing took place on September 17, 2025. A total of 14.4 million shares were successfully placed to at least 6 subscribers by the placing agent at a placing price of HK$4.33 per share. Based on the reasonable inquiries made by the directors, they are deeply aware, fully informed, and confident that the subscribers and their respective ultimate beneficial owners are independent third parties.
The net proceeds from the placing are approximately HK$59.34 million.
Related Articles
HKBN(01310): Tender offer deadline reached, offeror and its concerted action parties hold 78.08% of shares.
Yinbang Clad Material (300337.SZ) Shareholder Wuxi Xinbang intends to collectively reduce its shareholding by no more than 3%.
Eli Lilly (LLY.US) establishes a global weight loss drug strategy: replicating the successful model in the United States, but adopts a cautious attitude towards fast approval of new drugs.
HKBN(01310): Tender offer deadline reached, offeror and its concerted action parties hold 78.08% of shares.
Yinbang Clad Material (300337.SZ) Shareholder Wuxi Xinbang intends to collectively reduce its shareholding by no more than 3%.
Eli Lilly (LLY.US) establishes a global weight loss drug strategy: replicating the successful model in the United States, but adopts a cautious attitude towards fast approval of new drugs.
